Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-blind, Placebo-controlled Study With Additional Open-label, Single-blind and Placebo-controlled Cohorts to Assess the Safety, Tolerability, and Efficacy of NGM282 in Patients With Nonalcoholic Steatohepatitis
The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
NGM Clinical Study Site 922
Chandler, Arizona, United States
NGM Clinical Study Site 923
Tucson, Arizona, United States
NGM Clinical Study Site 924
Los Angeles, California, United States
NGM Clinical Study Site 901
San Diego, California, United States
NGM Clinical Study Site 902
Denver, Colorado, United States
NGM Clinical Study Site 917
Lakewood Rch, Florida, United States
NGM Clinical Study Site 906
Chicago, Illinois, United States
NGM Clinical Study Site 918
Kansas City, Missouri, United States
NGM Clinical Study Site 903
Durham, North Carolina, United States
NGM Clinical Study Site 921
Germantown, Tennessee, United States
Start Date
July 31, 2015
Primary Completion Date
December 6, 2019
Completion Date
January 17, 2020
Last Updated
July 23, 2025
254
ACTUAL participants
NGM282
BIOLOGICAL
Placebo
OTHER
Lead Sponsor
NGM Biopharmaceuticals, Inc
Collaborators
NCT06216041
NCT04104321
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04616014